[Korean Startup Interview] How HOYA LAB is Tackling Gene Therapy’s Toughest Problem with AI

This interview with the founder of HOYA LAB discusses the company's approach to solving a major hurdle in gene therapy development: minimizing off-target effects. These unintended edits can cause severe side effects, and HOYA LAB addresses this by integrating artificial intelligence (AI) with biotechnology to design more precise gene-editing tools. The company aims to provide optimized guide RNAs to other biotech firms, reducing the time and cost of developing therapies for various genetic disorders, starting with AIDS, ocular diseases, and muscle disorders. HOYA LAB believes its bio-AI approach, which combines expertise in both fields, offers a significant competitive advantage in this rapidly evolving market.